Introduction: A Nuclear Vision for Viksit Bharat@2047 As India marches toward its ambitious goal of becoming a developed nation by 2047, energy security stands as a pivotal pillar in the vision of Viksit Bharat . Amid the global climate crisis and rising energy demands, nuclear power has re-emerged as a compelling solution. India’s commitment to achieving 100 GW of nuclear power capacity by 2047 is both visionary and necessary—but achieving this requires a strategic shift in policy, participation, and international cooperation. While India’s nuclear energy sector has traditionally been a tightly controlled domain under government monopoly—primarily led by the Department of Atomic Energy (DAE) and Nuclear Power Corporation of India Limited (NPCIL) —it is now imperative to welcome private sector investments and foreign partnerships. A reformed nuclear ecosystem can unlock the full potential of atomic energy as a clean, reliable, and scalable contributor to India’s net-zero aspiration...
The global biosimilar market is expanding rapidly, with pharmaceutical companies forging strategic alliances to enhance their reach and market share. In a significant development, Dr. Reddy’s Laboratories and China’s Bio-Thera Solutions have signed an agreement to introduce two biosimilars in the Southeast Asian market . This partnership reflects the growing demand for affordable biologic alternatives and strengthens both companies' presence in the global biopharmaceutical landscape . Why This Deal Matters With the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, the demand for biosimilars is soaring. Biologic drugs , while highly effective, are often expensive, creating accessibility challenges in emerging markets like Southeast Asia. This collaboration between Dr. Reddy’s and Bio-Thera aims to bridge this gap by offering cost-effective, high-quality biosimilars . Key Highlights of the Agreement 1. Focus on Two Biosimilar Products Th...